InflaRx (NasdaqGS:IFRX) 2026 Conference Transcript

Summary of InflaRx Conference Call Company Overview - Company: InflaRx - Industry: Biotechnology - Headquarters: Germany and the U.S. - IPO: Listed on NASDAQ in 2017 - Focus: Development of drugs targeting terminal complement inhibition, specifically C5a and C5a receptor 1 Key Molecules - Vilobelimab: Antibody targeting C5a - Izicopan: Small molecule targeting C5a receptor 1 - Recently completed a positive proof of concept Phase 2a study [2][5] Differentiation of Izicopan - Pharmacological Properties: - Higher bioavailability and plasma levels compared to avacopan (Amgen's drug) - Faster onset of receptor inhibition, achieving peak levels in days versus avacopan's 13 weeks [5][6] - Significantly lower inhibition of CYP3A4, reducing potential drug-drug interactions [6] - Safety Profile: - No observed hepatotoxicity in 200 treated patients, contrasting with avacopan's reported issues [8][9] Market Opportunities - Potential Market Impact: If avacopan were withdrawn, InflaRx sees an opportunity to position izicopan favorably [13] - Hidradenitis Suppurativa (HS): - Conducted a 28-day study showing promising results, including reduction of draining tunnels and pain [15][16] - Data compared favorably to existing treatments, indicating a potential best-in-class profile [27] Future Development Plans - Next Steps: - Planning a Phase 2B study, as the initial four-week trial does not suffice for pivotal trials [23] - Ongoing discussions with the FDA regarding dosing and trial design [21][25] - Capital Markets Day: Expected in spring, with disclosures on HS and other indications [24][36] Financial Position - Cost Reduction: Fixed costs reduced by approximately 30% due to the deprioritization of vilobelimab and related activities [33] Additional Indications - Chronic Spontaneous Urticaria (CSU): Encouraging data suggests potential for further trials, contingent on resources [30][32] Conclusion InflaRx is positioned to leverage its differentiated drug izicopan in the competitive landscape of autoimmune diseases, particularly HS and potentially CSU, while maintaining a strong safety profile and reducing operational costs. The upcoming Capital Markets Day will provide further insights into their strategic direction and clinical development plans.